0
Startups & Venture·October 23, 2026·1 min read

OpenAI Targets $1.25 Trillion Valuation in New Funding Round

Share

A $30B raise at a targeted $1.25T valuation would turn OpenAI into a macro asset class, not just a vendor—its roadmap and pricing will directly influence indices and capital allocation. For operators, that concentration means vendor risk and platform dependency are now board-level topics, not just procurement details.

Startups & Venture

Pathos AI, which uses AI to develop oncology drugs, raised a $237M Series E at a $3B post-money valuation, up from a $1.6B valuation in May 2025

Pathos AI nearly doubling valuation to $3B in ~18 months on a $237M Series E is a clear vote that AI-native drug discovery—especially in oncology—is moving from story to pipeline. If you’re a traditional biotech, expect investors and partners to benchmark your discovery engine against AI-first peers on cycle time and hit quality, not just clinical endpoints.